tiprankstipranks
Trending News
More News >
Advertisement

JIRE - AI Analysis

Compare

Top Page

JIRE

JPMorgan International Research Enhanced Equity ETF (JIRE)

Rating:67Neutral
Price Target:
$81.00
The JPMorgan International Research Enhanced Equity ETF (JIRE) has a solid overall rating, driven by strong contributions from holdings like ASML Holding NV and AstraZeneca. ASML stands out for its robust financial performance and revenue growth, while AstraZeneca benefits from a strong pipeline and strategic growth initiatives. However, weaker holdings such as Banco Santander, with declining revenue growth and liquidity challenges, may have slightly held back the fund’s rating. The ETF’s diversification across sectors and regions helps mitigate risks, though concentration in specific industries could pose challenges.
Positive Factors
Strong Top Holdings
Several key holdings, such as ASML Holding NV and SAFRAN SA, have delivered strong year-to-date performance, supporting the ETF's overall returns.
Global Diversification
The ETF has exposure to a wide range of countries, including Japan, the UK, and France, reducing reliance on any single economy.
Low Expense Ratio
With an expense ratio of 0.24%, the ETF is cost-efficient compared to many actively managed funds, helping investors retain more of their returns.
Negative Factors
Underperforming Holding
SAP SE, one of the top holdings, has shown negative year-to-date performance, which could drag on the fund's overall returns.
Sector Concentration Risk
The ETF is heavily weighted toward Financials and Industrials, which could make it vulnerable if these sectors face downturns.
Limited U.S. Exposure
With only 3.4% allocated to U.S. companies, the fund may miss out on opportunities in the world's largest economy.

JIRE vs. SPDR S&P 500 ETF (SPY)

JIRE Summary

The JPMorgan International Research Enhanced Equity ETF (JIRE) is an investment fund that focuses on companies outside the United States, offering exposure to global markets. It includes a mix of large, mid, and small companies from various countries like Japan, the UK, and Germany, and covers industries such as financials, technology, and healthcare. Some well-known companies in the fund are Nestlé and AstraZeneca. Investors might consider JIRE for diversification, as it provides access to international markets and industries. However, new investors should be aware that the fund’s performance can be affected by global economic changes and currency fluctuations.
How much will it cost me?The JPMorgan International Research Enhanced Equity ETF (JIRE) has an expense ratio of 0.24%, which means you’ll pay $2.40 per year for every $1,000 invested. This is lower than the average for actively managed ETFs because it aims to balance costs while leveraging JPMorgan's research to enhance returns.
What would affect this ETF?JIRE's focus on developed markets outside North America and its exposure to sectors like Financials and Industrials could benefit from global economic growth and infrastructure investments. However, challenges such as rising interest rates or regulatory changes in key regions could negatively impact its holdings, particularly in sectors like Technology and Financials. Additionally, geopolitical tensions or slower growth in Europe could pose risks to its top holdings like ASML and AstraZeneca.

JIRE Top 10 Holdings

The JPMorgan International Research Enhanced Equity ETF (JIRE) leans heavily on developed markets outside North America, with a notable focus on financials and industrials. ASML Holding NV is a standout performer, riding strong revenue growth and profitability, while Nestlé offers steady gains despite margin pressures. AstraZeneca and Roche are contributing positively, buoyed by robust pipelines and strategic growth initiatives. However, SAP SE is lagging, weighed down by valuation concerns and mixed technical signals. The fund’s diverse sector exposure provides balance, but its reliance on a few key names in financials and healthcare shapes its trajectory.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
ASML Holding NV2.67%$240.14M€351.20B38.18%
78
Outperform
AstraZeneca2.02%$181.82M£194.71B7.56%
75
Outperform
Shell (UK)1.89%$170.71M£165.60B14.14%
77
Outperform
Siemens1.70%$153.04M€192.47B35.64%
74
Outperform
Nestlé SA1.52%$137.02MCHF198.32B2.56%
65
Neutral
Banco Santander1.43%$129.18M€133.41B97.63%
66
Neutral
SAP SE1.41%$126.99M€261.78B4.56%
73
Outperform
SAFRAN SA1.39%$125.21M€126.53B45.69%
67
Neutral
Allianz1.39%$124.95M€136.21B20.42%
74
Outperform
UniCredit SpA1.19%$107.43M€99.18B69.19%
75
Outperform

JIRE Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
73.51
Positive
100DMA
72.00
Positive
200DMA
68.19
Positive
Market Momentum
MACD
0.47
Negative
RSI
56.62
Neutral
STOCH
80.57
Negative
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For JIRE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 74.50, equal to the 50-day MA of 73.51, and equal to the 200-day MA of 68.19, indicating a bullish trend. The MACD of 0.47 indicates Negative momentum. The RSI at 56.62 is Neutral, neither overbought nor oversold. The STOCH value of 80.57 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for JIRE.

JIRE Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$9.14B0.24%
67
Neutral
$4.79B0.29%
66
Neutral
$1.22B0.54%
65
Neutral
$114.24M0.39%
66
Neutral
$58.10M0.58%
61
Neutral
$39.35M0.56%
67
Neutral
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JIRE
JPMorgan International Research Enhanced Equity ETF
74.90
13.80
22.59%
FENI
Fidelity Enhanced International ETF
CGIE
Capital Group International Equity ETF
IMOM
Alpha Architect International Quantitative Momentum ETF
AIVI
WisdomTree International AI Enhanced Value Fund
QUIZ
Zacks Quality International ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement